Calendula Officinalis Extract

What is it?

Calendula officinalis extract is derived from the flower heads of the pot marigold, a Mediterranean plant cultivated for medicinal use since at least the 12th century. The extract contains a diverse phytochemical profile dominated by triterpenoid saponins (particularly faradiol and its esters), flavonoids (quercetin, isorhamnetin, narcissin), carotenoids (lutein, zeaxanthin, beta-carotene), polysaccharides, and essential oils. Faradiol is considered the primary anti-inflammatory compound — studies have shown it inhibits croton oil-induced ear edema in vivo with potency approaching that of indomethacin, a prescription NSAID. Calendula's anti-inflammatory mechanism involves multiple pathways: inhibition of lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, suppression of pro-inflammatory cytokines including TNF-alpha and IL-1beta, and modulation of NF-kB signaling. Beyond inflammation control, calendula has demonstrated significant wound-healing properties through mechanisms including stimulation of angiogenesis, promotion of granulation tissue formation, increase of collagen synthesis by fibroblasts, and acceleration of epithelialization. The polysaccharide fraction of calendula activates macrophages and promotes the production of reactive oxygen species for antimicrobial defense without causing excessive tissue damage — a carefully calibrated immune response. Calendula is recognized for its exceptional gentleness: it is one of the few botanical extracts recommended by dermatologists for use on newborn skin, post-radiation dermatitis, and severely compromised barriers. The European Medicines Agency (EMA) has granted calendula a traditional herbal medicine registration for wound healing and skin inflammation, and it is listed in multiple pharmacopoeias. In skincare, calendula extract is used at 0.5–5% in creams, serums, and oils, with whole-flower infusions common in cleansing oils and body care products. Its combination of potent bioactivity and extreme gentleness makes it uniquely suited for sensitive, reactive, and post-procedure skin.

How It Works

1. 1

   Selective Anti-Inflammatory Control

   Faradiol inhibits COX and LOX enzymes to reduce inflammatory mediators without suppressing the regenerative processes PDRN activates.

2. 2

   Angiogenesis Promotion

   Calendula's triterpenoids promote new blood vessel formation, complementing PDRN's VEGF-driven angiogenesis for improved tissue perfusion.

3. 3

   Macrophage Modulation

   Polysaccharides activate macrophages for antimicrobial defense and debris clearance, preparing a clean environment for PDRN-driven regeneration.

4. 4

   Epithelialization Support

   Calendula accelerates keratinocyte migration and wound closure at the surface while PDRN rebuilds the dermal matrix underneath.

Role in PDRN

Calendula and PDRN represent the ideal pairing for sensitive and compromised skin types that need regeneration without irritation risk. PDRN's A2A receptor activation drives fibroblast proliferation and tissue repair, but sensitive skin often reacts to the metabolic byproducts of accelerated cellular activity with redness and discomfort. Calendula addresses this vulnerability through its faradiol-mediated anti-inflammatory action — reducing the inflammatory response that accompanies tissue remodeling without suppressing the regenerative process itself. This selective anti-inflammatory profile is crucial: calendula calms the symptoms of healing (redness, swelling, irritation) while leaving the constructive processes (fibroblast proliferation, collagen deposition, angiogenesis) intact. Both ingredients independently promote wound healing through complementary mechanisms: PDRN stimulates fibroblasts through A2A adenosine signaling, while calendula's triterpenoids and polysaccharides promote angiogenesis, granulation tissue formation, and epithelialization through growth factor modulation and macrophage activation. The convergence of these independent wound-healing pathways creates an additive effect that is particularly valuable in post-procedure recovery. Calendula's exceptional safety profile — suitable for newborns and radiation-damaged skin — means it can be introduced earlier in post-treatment protocols than most actives, providing soothing support during the critical early healing window when PDRN-stimulated regeneration is most active.

Clinical Data

Calendula's wound-healing efficacy is supported by both traditional use and modern clinical research. A 2009 systematic review in Wound Repair and Regeneration analyzed multiple controlled trials and concluded that calendula preparations significantly accelerated wound healing and reduced inflammation compared to controls. A notable 2004 RCT published in the Journal of Clinical Oncology found that calendula ointment was significantly more effective than trolamine in preventing acute dermatitis during breast cancer radiation therapy, with grade 2-3 dermatitis occurring in only 41% of the calendula group versus 63% of controls. A 2012 study in the Journal of Wound Care demonstrated that calendula extract significantly increased fibroblast proliferation and collagen synthesis in vitro, with dose-dependent effects on type I and type III collagen production. The anti-inflammatory potency of faradiol has been confirmed in multiple pharmacological studies, with one showing inhibition of croton oil-induced edema by up to 60%. In the context of PDRN combination therapy, calendula's demonstrated ability to accelerate wound healing through mechanisms complementary to PDRN — particularly its gentle anti-inflammatory action and angiogenesis promotion — suggests synergistic potential for post-procedure recovery and sensitive skin repair.

Product Formats in the Wild

Common ways this ingredient is delivered in clinical and consumer products.